IFNA1 and melanoma: STING agonists, immune checkpoint blockade (ICB), and other IFN-inducing therapies have been promising for patients with cancer; however, they are not always the frontline or the most effective and durable treatment strategies for melanoma, due to high rates of immune-related adverse events [22,28,29].